BASEL, SWITZERLAND--(Marketwire - October 08, 2007) - Basilea Pharmaceutica Ltd. (SWX: BSLN) announced today that Swissmedic has accepted for assessment the marketing authorization application of ceftobiprole for the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot infections. The application is subject to an accelerated review. The regulatory dossier was submitted by Basilea's license partner Janssen-Cilag AG, a Johnson & Johnson company.
